Stockscreener 앱 받기
5.40
3.40%
-0.19
시간 외 거래:
5.40
Insight Molecular Diagnostics Inc 주식(IMDX)의 최신 뉴스
Insight Molecular Diagnostics Inc. Actuals & Estimates (BOATS:IMDX) - TradingView
IMDX Forecast — Price Target — Prediction for 2027 - TradingView
Insight Molecular Diagnostics and ASTS Award Grant for Health Economics Study of In-House vs. Send-Out dd-cfDNA Testing in Kidney Transplantation - Quiver Quantitative
iMDx and ASTS fund $100,000 study on kidney transplant testing costs - Stock Titan
Insight Molecular Diagnostics Ord Shs (IMDX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Insight Molecular Diagnostics Ord Shs (IMDX) Institutional Confidence - TradingKey
IMDX SEC FilingsInsight Molecular Diagnostics Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Insight Molecular Diagnostics Validates GraftAssure Assay Superiority - HarianBasis.co
Breakthrough Science Meets Market Skepticism: Insight Molecular Diagnostics Inc. (IMDX)’s Defining Moment - Insider Monkey
12 High-Growth Micro-Cap Stocks to Buy Now - Insider Monkey
Insight Molecular Diagnostics Ord Shs (IMDX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Insight Molecular Diagnostics (NASDAQ: IMDX) shareholders back plan share increase - Stock Titan
Insight Molecular Diagnostics Inc. Announces Favorable Head-To-Head Data On Imdx's Graftassure With Competing NGS Assay Published In Clinical Chemistry - marketscreener.com
New lab test rivals DNA sequencing to monitor kidney transplants - Stock Titan
Favorable Head-to-Head Data on iMDx’s GraftAssure with Competing NGS Assay Published in Clinical Chemistry - Sahm
[Form 4] Insight Molecular Diagnostics Inc. Insider Trading Activity - Stock Titan
Director Arno Andrew of Insight Molecular (IMDX) receives 32,331-share stock grant - Stock Titan
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) Stock Price, News & Analysis - Kalkine
IMDX Q1 2026 Earnings: Narrowing Losses with 55% EPS Surprise Amid Revenue DisclosuresBuyback Announcement Report - newsline.com
Insight Molecular Diagnostics Inc. Announces Publication of GraftAssure CM-Score Demonstrating Superior Performance in Transplant Rejection Monitoring - Quiver Quantitative
IMDX GraftAssure Assay Sets New Standard in Screening - GlobeNewswire
IMDX GraftAssure Assay Sets New Standard in Screening Kidney Transplant Patients Per American Journal of Transplantation - Yahoo Finance Australia
Study: New kidney transplant model doubles reliability of positive results - Stock Titan
iMDx to Highlight In-House Transplant Testing Opportunity and Host Key Opinion Leaders at American Transplant Congress - The Manila Times
IMDX Q1 2026 Earnings: EPS Beat Lifts Sentiment Despite No RevenueForward EPS Estimate - newsline.com
Insight Molecular Diagnostics Inc Highlights Graftassure Technology and Announces Grant Winners At American Transplant Congress - marketscreener.com
iMDx to Showcase GraftAssure Technology at American Transplant Congress and Announce Research Grant Winners - Quiver Quantitative
In-house transplant rejection test heads to key Boston conference - Stock Titan
Lake Street Maintains Insight Molecular Diagnostics(IMDX.US) With Buy Rating, Maintains Target Price $12 - Moomoo
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
IMDX Q1 2026 Earnings: Strong EPS Beat Driven by Cost Discipline and Operational EfficiencyEarnings Decline Risk - newsline.com
Insight Molecular Diagnostics (IMDX) Posts Modest Gain; Resistance Test LoomsFactor Crowding - newsline.com
IMDX Q1 2026 Earnings: EPS beats estimates by 55% despite revenue absenceFiscal Year Earnings - newsline.com
Insight Molecular Diagnostics (IMDX) Rallies 5.75% as Bullish Momentum Builds Near Key ResistanceSynthetic Short - newsline.com
Insight Molecular Diagnostics Inc. (IMDX) Q1 2026 Earnings: EPS Surprises to the Upside During Pre‑Revenue Phase - The Legal Advocate
Earnings call transcript: Insight Molecular Diagnostics’ Q1 2026 performance and strategic outlook - Investing.com Australia
Insight Molecular Diagnostics Balances Progress and Cash Burn - TipRanks
Insight Molecular Diagnostics Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:IMDX) 2026-05-17 - Seeking Alpha
Lake Street Remains a Buy on Insight Molecular Diagnostics (IMDX) - The Globe and Mail
How Insight Molecular Diagnostics (IMDX) Story Is Shifting With Fresh Capital And GraftAssureDx Submission - Yahoo Finance
BTIG reiterates Neutral on Insight Molecular stock amid FDA review By Investing.com - Investing.com Nigeria
BTIG reiterates Neutral on Insight Molecular stock amid FDA review - Investing.com India
Insight Molecular Q1 2026 Earnings Call Transcript - Sahm
Insight Molecular Diagnostics Inc (IMDX) Q1 2026 Earnings Call H - GuruFocus
Needham Maintains Insight Molecular Diagnostics(IMDX.US) With Buy Rating, Maintains Target Price $9 - Moomoo
Insight Molecular Diagnostics (IMDX) Sees Positive Engagement wi - GuruFocus
Insight Molecular Diagnostics expects about $0.25M Q2 2026 revenue while projecting second-quarter cash burn above $9M - MSN
Insight Molecular Diagnostics (IMDX) Q1 2026 Earnings: EPS not d - GuruFocus
Insight Molecular Diagn 1Q Rev $32,000 >IMDX - Moomoo
Insight Molecular Diagnostics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Earnings call transcript: Insight Molecular Diagnostics Q1 2026 sees stock rise 2.41% - Investing.com Australia
IMDX Q1 2026 Earnings Call Transcript - The Globe and Mail
Insight Molecular Diagnostics Inc Q1 Net Income USD -4.29 Million - TradingView
1.76%
0.62%
자본화:
|
볼륨(24시간):